Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease

被引:51
|
作者
Dal Bello-Haas, Vanina [1 ]
Florence, Julaine M. [2 ]
机构
[1] McMaster Univ, Sch Rehabil Sci, Hamilton, ON L8S 1C7, Canada
[2] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2013年 / 05期
关键词
Amyotrophic Lateral Sclerosis [psychology; therapy; Exercise Therapy [methods; Exercise Tolerance; Motor Neuron Disease [psychology; Physical Endurance; Quality of Life; Randomized Controlled Trials as Topic; Humans; RESISTANCE EXERCISE; NATURAL-HISTORY; MOUSE MODEL; HEALTH-STATUS; RATING-SCALE; ALS; REHABILITATION; INDIVIDUALS; VALIDATION; SURVIVAL;
D O I
10.1002/14651858.CD005229.pub3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Despite the high incidence of muscle weakness in individuals with amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND), the effects of exercise in this population are not well understood. This is an update of a review first published in 2008. Objectives To systematically review randomised and quasi-randomised studies of exercise for people with ALS or MND. Search methods We searched The Cochrane Neuromuscular Disease Group Specialized Register (2 July 2012), CENTRAL (2012, Issue 6 in The Cochrane Library), MEDLINE (January 1966 to June 2012), EMBASE (January 1980 to June 2012), AMED (January 1985 to June 2012), CINAHL Plus (January 1938 to June 2012), LILACS (January 1982 to June 2012), Ovid HealthSTAR (January 1975 to December 2012). We also searched ProQuest Dissertations & Theses A&I (2007 to 2012), inspected the reference lists of all papers selected for review and contacted authors with expertise in the field. Selection criteria We included randomised or quasi-randomised controlled trials of people with a diagnosis of definite, probable, probable with laboratory support, or possible ALS, as defined by the El Escorial criteria. We included progressive resistance or strengthening exercise, and endurance or aerobic exercise. The control condition was no exercise or standard rehabilitation management. Our primary outcome measure was improvement in functional ability, decrease in disability or reduction in rate of decline as measured by a validated outcome tool at three months. Our secondary outcome measures were improvement in psychological status or quality of life, decrease in fatigue, increase in, or reduction in rate of decline of muscle strength (strengthening or resistance studies), increase in, or reduction in rate of decline of aerobic endurance (aerobic or endurance studies) at three months and frequency of adverse effects. We did not exclude studies on the basis of measurement of outcomes. Data collection and analysis Two review authors independently assessed trial quality and extracted the data. We collected adverse event data from included trials. The review authors contacted the authors of the included studies to obtain information not available in the published articles. Main results We identified two randomised controlled trials that met our inclusion criteria, and we found no new trials when we updated the searches in 2012. The first, a study with overall unclear risk of bias, examined the effects of a twice-daily exercise program of moderate load endurance exercise versus "usual activities" in 25 people with ALS. The second, a study with overall low risk of bias, examined the effects of thrice weekly moderate load and moderate intensity resistance exercises compared to usual care (stretching exercises) in 27 people with ALS. After three months, when the results of the two trials were combined (43 participants), there was a significant mean improvement in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) measure of function in favour of the exercise groups (mean difference 3.21, 95% confidence interval 0.46 to 5.96). No statistically significant differences in quality of life, fatigue or muscle strength were found. In both trials adverse effects, investigators reported no adverse effects such as increased muscle cramping, muscle soreness or fatigue Authors' conclusions The included studies were too small to determine to what extent strengthening exercises for people with ALS are beneficial, or whether exercise is harmful. There is a complete lack of randomised or quasi-randomised clinical trials examining aerobic exercise in this population. More research is needed.
引用
收藏
页数:36
相关论文
共 50 条
  • [31] Amyotrophic Lateral Sclerosis: the Role of Exercise
    Lisle, Stuart
    Tennison, Matthew
    CURRENT SPORTS MEDICINE REPORTS, 2015, 14 (01) : 45 - 46
  • [32] Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis
    Allen, Scott P.
    Hall, Benjamin
    Castelli, Lydia M.
    Francis, Laura
    Woof, Ryan
    Siskos, Alexandros P.
    Kouloura, Eirini
    Gray, Elizabeth
    Thompson, Alexander G.
    Talbot, Kevin
    Higginbottom, Adrian
    Myszczynska, Monika
    Allen, Chloe F.
    Stopford, Matthew J.
    Hemingway, Jordan
    Bauer, Claudia S.
    Webster, Christopher P.
    De Vos, Kurt J.
    Turner, Martin R.
    Keun, Hector C.
    Hautbergue, Guillaume M.
    Ferraiuolo, Laura
    Shaw, Pamela J.
    BRAIN, 2019, 142 : 586 - 605
  • [33] Physical-therapeutic exercise program for rehabilitation of people with amyotrophic lateral sclerosis
    Canadilla-Barrios, Yordan
    Mesa-Anoceto, Magda
    Bosque-Jimenez, Jerry
    Caridad Canete-Rojas, Annia
    ARRANCADA, 2021, 21 (38): : 208 - 230
  • [34] Ferroptosis mediates selective motor neuron death in amyotrophic lateral sclerosis
    Wang, Taide
    Tomas, Doris
    Perera, Nirma D.
    Cuic, Brittany
    Luikinga, Sophia
    Viden, Aida
    Barton, Samantha K.
    McLean, Catriona A.
    Samson, Andre L.
    Southon, Adam
    Bush, Ashley I.
    Murphy, James M.
    Turner, Bradley J.
    CELL DEATH AND DIFFERENTIATION, 2022, 29 (06) : 1187 - 1198
  • [35] Therapeutic Development in Amyotrophic Lateral Sclerosis
    Bucchia, Monica
    Ramirez, Agnese
    Parente, Valeria
    Simone, Chiara
    Nizzardo, Monica
    Magri, Francesca
    Dametti, Sara
    Corti, Stefania
    CLINICAL THERAPEUTICS, 2015, 37 (03) : 668 - 680
  • [36] Executive dysfunction and survival in patients with amyotrophic lateral sclerosis: Preliminary report from a Serbian centre for motor neuron disease
    Stojkovic, Tanja
    Stefanova, Elka
    Pekmezovic, Tatjana
    Peric, Stojan
    Stevic, Zorica
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2016, 17 (7-8) : 543 - 547
  • [37] UNMASKING THE SILENT MOTOR NEURON LOSS IN AMYOTROPHIC LATERAL SCLEROSIS
    Neuwirth, Christoph
    Weber, Markus
    MUSCLE & NERVE, 2018, 58 (02) : 184 - 185
  • [38] Regulatory T cells for amyotrophic lateral sclerosis/motor neuron disease: A clinical and preclinical systematic review
    Rajabinejad, Misagh
    Ranjbar, Sedigheh
    Afshar Hezarkhani, Leila
    Salari, Farhad
    Gorgin Karaji, Ali
    Rezaiemanesh, Alireza
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (06) : 5030 - 5040
  • [39] Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease
    Beauverd, Michel
    Mitchell, J. D.
    Wokke, John H. J.
    Borasio, Gian Domenico
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (11):
  • [40] Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease
    Diana, Andrea
    Pillai, Rita
    Bongioanni, Paolo
    O'Keeffe, Aidan G.
    Miller, Robert G.
    Moore, Dan H.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (01):